Pfizer, BioNTech begin phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate

This article was originally published here

Both companies have decided to advance their BNT162b2 vaccine candidate into the phase 2/3 study at a 30µg dose level in a two-dose regimen after an extensive assessment

The post Pfizer, BioNTech begin phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply